| Attributes | Values |
|---|
| rdf:type
| |
| description
| - wetenschappelijk artikel (nl)
- наукова стаття, опублікована в січні 1993 (uk)
- article scientifique publié en 1993 (fr)
- im Januar 1993 veröffentlichter wissenschaftlicher Artikel (de)
- artículu científicu espublizáu en xineru de 1993 (ast)
- artikull shkencor i botuar më 01 janar 1993 (sq)
- scientific article published on 01 January 1993 (en)
|
| publication date
| |
| publication date
| |
| exact match
| |
| exact match
| |
| cites work
| |
| cites work
| - Statistical aspects of the analysis of data from retrospective studies of disease
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group
- Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation
- 352. Note: Conservatism of the Approximation Σ(O - E) 2 /E in the Logrank Test for Survival Data or Tumor Incidence Data
- Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer
- Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel
- CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH MELPHALAN FOR BREAST CANCER
- Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials
- A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group
- Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group
- Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values
- The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma--7-yr results
- Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis
- Antiestrogen treatment of postmenopausal women with primary high risk breast cancer
- Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: Five-year results
- Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study
- Adjuvant tamoxifen and chemotherapy in stage II breast cancer: interim findings from NSABP protocol B-09
- Distant recurrence in breast cancer. Survival expectations and first choice of chemotherapy regimen
- Adjuvant chemotherapy in stage II breast cancer: a brief overview of the NSABP clinical trials
|
| author name string
| |
| author name string
| - M Héry
- A Monnier
- M Namer
- J P Gérard
- F Plat
- D Serin
- J P Jacquin
- D Gedouin
- E Cabarrot
- M J Goudier
|
| rdfs:label
| - Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (nl)
- Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group (en)
- Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group (sq)
|
| skos:prefLabel
| - Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (nl)
- Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group (en)
- Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group (sq)
|
| name
| - Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (nl)
- Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group (en)
- Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group (sq)
|
| title
| |
| title
| - Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| main subject
| |
| main subject
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| volume
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| - 10.2165/00003495-199300452-00010
|
| Dimensions Publication ID
| |
| Dimensions Publication ID
| |
| is about
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)